

# American National Standard

ANSI/AAMI/ISO 10993-6:1995/(R)2001

## Biological evaluation of medical devices, Part 6: Tests for local effects after implantation



**Association for the Advancement  
of Medical Instrumentation**

1110 N. Glebe Rd., Suite 220  
Arlington, VA 22201-4795

© 2000 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

**Copyright and Permissions**

Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of these documents without the prior written permission of the Association for the Advancement of Medical Instrumentation or the copyright holder (if not AAMI) is prohibited by law. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of these documents (whether internally or externally) without the prior written permission of the copyright holder. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of these documents, contact AAMI, 1110 N. Glebe Road, Suite 220, Arlington, VA 22201-4795. Phone: (703) 525-4890; Fax: (703) 525-1067.

**Violators of this copyright policy should be reported to AAMI's legal counsel:**

**McKenna & Cuneo, L.L.P.  
1900 K Street, N.W.  
Washington, DC 20006  
Attn: Jacqueline A. Henson, Esq.  
Phone: (202) 496-7500**

**Biological evaluation of medical devices—  
Part 6: Tests for local effects after implantation**

American National Standard

ANSI/AAMI/ISO 10993-6:1995/(R)2001

**Biological evaluation of medical devices—Part 6: Tests for local effects after implantation**

Approved 17 November 1994 by

**Association for the Advancement of Medical Instrumentation**

Approved 3 January 1995 and reaffirmed 20 November 2001 by

**American National Standards Institute, Inc.**

**Abstract:**

This standard specifies test methods for the assessment of the local effects of an implant material on living tissue, at both the macroscopic and microscopic level.

**Association for the Advancement of Medical Instrumentation**

The adoption of ISO 10993-6:1994 as an American National Standard was initiated by the AAMI Biological Evaluation Committee, which also functions as a U.S. Technical Advisory Group to the relevant work in the International Organization for Standardization (ISO). U.S. representatives from the AAMI Implantation Working Group (U.S. Sub-TAG for ISO/TC 194/WG 10), cochaired by Donald F. Gibbons, PhD, of 3M Life Sciences Sector and Howard P. Greisler, MD, of the Foster G. McGaw Hospital, played an active part in developing the ISO standard.

The AAMI **Biological Evaluation Committee** has the following members:

*Cochair:* Paul Didisheim, MD

*Members:* James M. Anderson, MD, PhD, Case Western Reserve University  
Sumner A. Barenberg, Cambridge Consulting, Ltd., Chicago, IL  
Arthur J. Coury, PhD, Society for Biomaterials  
Roger Dabbah, PhD, U.S. Pharmacopeial Convention, Inc.  
Paul Didisheim, MD, National Heart, Lung, and Blood Institute  
Robert L. Fuson, MD, Bristol-Myers Squibb  
Donald Gibbons, PhD, 3M Life Sciences Sector  
Jean A. Goggins, PhD, Meadox Medicals, Inc.  
Sharon Northup, PhD, Baxter Healthcare Corporation  
Barry F. Page, Consultant, Garner, NC  
John W. Stanford, PhD, American Dental Association  
Mel Stratmeyer, PhD, FDA Center for Devices and Radiological Health

*Alternates:* John G. Miller, DVM, National Institutes of Health  
Ed Mueller, FDA Center for Devices and Radiological Health  
Harold Stanley, DDS, American Dental Association

The AAMI **Implantation Working Group** has the following members:

*Cochairs:* Donald F. Gibbons, PhD  
Howard P. Greisler, MD

*Members:* Donald F. Gibbons, PhD, 3M Life Sciences Sector  
Howard P. Greisler, MD, Foster G. McGaw Hospital  
Emanuel Horowitz, PhD, Johns Hopkins University  
Nirmal Mishra, DVM, PhD, FDA Center for Devices and Radiological Health  
Joe Persivale, Johnson & Johnson  
Herbert N. Prince, PhD, Gibraltar Biological Labs  
Barry Sauer, DVM, Harrington Arthritis Research Center  
Myron Spector, PhD, Brigham & Womens Hospital  
Kenneth R. St. John, University of Mississippi Medical Center  
Harold Stanley, DDS, American Dental Association  
Andreas F. von Recum, PhD, Clemson University

NOTE—Participation by federal agency representatives in the development of this standard does not constitute endorsement by the federal government or any of its agencies.

### **Background of ANSI/AAMI adoption of ISO 10993-6:1994**

#### *Tests for local effects after implantation*

As indicated in the foreword to the main body of this document (page vi), the International Organization for Standardization (ISO) is a worldwide federation of national standards bodies. The United States is one of the ISO members that took an active role in the development of the first edition of the standard for tests for local effects after implantation.

AAMI and ANSI procedures require that standards be reviewed and, if necessary, revised every five years to reflect technological advances that may have occurred since publication. AAMI also encourages its committees to harmonize their work with international standards as much as possible.

The 10993 series of standards was created by Technical Committee ISO/TC 194, Biological evaluation of medical devices, to fill a need for the international harmonization of test methods for various kinds of biological aspects of medical devices.

This standard was developed so that there would be internationally agreed-upon tests for local effects after implantation.

U.S. participation in this ISO activity is through the U.S. Technical Advisory Group for ISO/TC 194, administered by the Association for the Advancement of Medical Instrumentation (AAMI).

The AAMI Biological Evaluation Committee (U.S. Technical Advisory Group for ISO/TC 194) supports international harmonization of methods used in evaluating biocompatibility of medical devices in order to help reduce unnecessary repetition of testing. The committee recommended in 1993 that AAMI initiate adoption of ISO 10993-6 in the United States as a new American National Standard and the proposal was approved 3 January 1995.

The concepts incorporated in this standard should not be considered inflexible or static. This standard, like any other, must be reviewed and updated periodically to assimilate progressive technological developments. To remain relevant, it must be modified as technological advances are made and as new data come to light.

Suggestions for improving this standard are invited. Comments and suggested revisions should be sent to Standards Department, AAMI, 3330 Washington Boulevard, Suite 400, Arlington, VA 22201.

NOTE—Beginning with the ISO foreword on page vi, this American National Standard is identical to ISO 10993-6:1994.

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75% of the member bodies casting a vote.

International Standard ISO 10993-6 was prepared by Technical Committee ISO/TC 194, Biological evaluation of medical devices.

ISO 10993 consists of the following parts, under the general title *Biological evaluation of medical devices*:

- Part 1: *Guidance on selection of tests*
- Part 2: *Animal welfare requirements*
- Part 3: *Tests for genotoxicity, carcinogenicity and reproductive toxicity*
- Part 4: *Selection of tests for interactions with blood*
- Part 5: *Tests for cytotoxicity: in vitro methods*
- Part 6: *Tests for local effects after implantation*
- Part 7: *Ethylene oxide sterilization residuals*
- Part 9: *Degradation of materials related to biological testing* [Technical Report]
- Part 10: *Tests for irritation and sensitization*
- Part 11: *Tests for systemic toxicity*
- Part 12: *Sample preparation and reference materials*
- Part 13: *Identification and quantification of degradation products from polymers*
- Part 14: *Identification and quantification of degradation products from ceramics*
- Part 15: *Identification and quantification of degradation products from coated and uncoated metals and alloys*
- Part 16: *General guidance on toxicokinetic study design for degradation products and leachables from medical devices*
- Part 17: *Glutaraldehyde and formaldehyde residues in industrially sterilized medical devices*

Future parts will deal with other relevant aspects of biological testing.

Annexes A, B and C of this part of ISO 10993 are for information only.

## Introduction

This International Standard gives methods of biological testing of medical and dental materials and devices, and their evaluation in regard to their biocompatibility.

ISO 10993-1 offers a guide for selection of methods for biological testing. The intention is to reduce animal tests to the justifiable minimum (see ISO 10993-2). A search of the literature precedes any testing, as data concerning the biological safety of the candidate material could be available.

The test methods described in this part of ISO 10993 are based on established implantation tests. This part of ISO 10993 describes animal tests for the study of local effects after implantation. The use of *in vivo* implantation techniques for characterizing the biological response of tissues to materials allows for the assessment of such materials not achieved by other procedures.

These test methods may not be appropriate for all types of medical devices. The user is cautioned to consider the appropriateness of the method in view of the materials being tested, their potential applications, and the recommendations contained in ISO 10993-1.

ISO/TC 194 appreciates any information for the further development of this part of ISO 10993.

## Biological evaluation of medical devices—Part 6: Tests for local effects after implantation

### 1 Scope

This part of ISO 10993 specifies test methods for the assessment of the local effects of an implant material on living tissue, at both the macroscopic and microscopic level.

The test specimen is implanted into a site and tissue appropriate for evaluation of the biological safety of the material. The implant is not intended to be subjected to mechanical or functional loading. The local effects are evaluated by a comparison of the tissue response caused by a test specimen to that caused by materials used in medical devices whose clinical acceptability has been established.

The test methods for local effects after implantation are used to assess subchronic effects (short-term, up to 12 weeks), or chronic effects (long-term, longer than 12 weeks).

### 2 Normative references

The following standards contain provisions which, through reference in this text, constitute provisions of this part of ISO 10993. At the time of publication, the editions indicated were valid. All standards are subject to revision, and parties to agreements based on this part of ISO 10993 are encouraged to investigate the possibility of applying the most recent editions of the standards indicated below. Members of IEC and ISO maintain registers of currently valid International Standards.

ISO 10993-1:1992, *Biological evaluation of medical devices — Part 1: Guidance on selection of tests*.

ISO 10993-2:1992, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*.

### 3 Common provisions for implantation test methods

#### 3.1 General

For the purposes of this part of ISO 10993, the definitions given in ISO 10993-1 and ISO 10993-2 apply.

The provisions in this clause shall apply to the test methods described in clauses 4 to 6.

It is important that the researcher plans the study in such detail that the maximum of information can be extracted from the use of each animal (see ISO 10993-2).

#### 3.2 Preparation of specimens for implantation

### **3.2.1 Solid specimens (excluding powders)**

Physical characteristics (that is form, density, hardness, surface finish) can influence the character of the tissue response to the test material.

Each implant shall be manufactured, processed, cleaned of contaminants and sterilized by the method intended for the final product.

After final preparation and sterilization, the implant specimens shall be handled in such a way as to ensure that they are not scratched, damaged or contaminated in any way prior to or during insertion.

### **3.2.2 Non-solid specimens (including powders)**

Non-solid specimens may be liquids, pastes and particulates, as distinct from the materials covered in [3.2.1](#). The components may be mixed before use (e.g., bone cements, dental materials), and set after varying time periods.

The materials may be contained in tubes for the purpose of testing for local effects after implantation. Polyethylene (PE), polypropylene (PP), or polytetrafluoroethylene (PTFE) tubes are commonly used for this purpose.

Prior to test the tubes shall be rinsed with 70% (V/V) ethanol and distilled water and sterilized by autoclaving or other appropriate methods relevant for clinical applications. Materials tested in their freshly mixed state shall be tested for microbiological contamination.

Prepare the test material according to the manufacturer's instructions and insert the material into the tube until level with the top. Exercise the utmost care to prevent contamination of the outer surface of the tube by the test material. Avoid entrapment of air in the tube and ensure that the end surfaces of the inserted material in the tube and the tube ends are smooth.

NOTE 1—PE tubes may be deformed by autoclaving. It is difficult to section PTFE tubes in the microtome, and substitution by PE or PP tubes of the same dimensions may be preferable when the tubes are to remain in the tissue blocks during sectioning.

### **3.2.3 Control specimens**

The size, shape, and especially the surface condition of the control(s) shall be as similar to that of the implant test specimens as is practically possible. When the test material is contained in a tube, the control shall be a rod of the same material as the tube and with the same diameter as the outer diameter of the tube. The control specimens shall be handled, cleaned and sterilized in such a manner as to maintain them as acceptable and well characterized controls.

Selection of control material(s) should be based on their established use in clinical applications similar to those proposed for the candidate test material and is not restricted to those indicated in [annex A](#) and [C.1](#).

## **3.3 Animals, tissues, test periods, surgery, postoperative care, euthanasia**

### **3.3.1 Animals and tissues**

Animal husbandry shall be in accordance with ISO 10993-2 and/or national regulatory requirements for laboratory animals.

Select an animal species with due consideration of the size of the implant test specimens, the intended duration of the test in relation to the expected life-span of the animals, as well as the recognized species differences in biological response in both hard and soft tissues.

For short-term testing in subcutaneous tissue and muscle, animals such as mice, rats, guinea-pigs and rabbits are commonly used. Select one species among these.

For long-term testing in subcutaneous tissue, muscle and bone, animals such as rats, guinea-pigs, rabbits, dogs, sheep, goats, pigs and other animals with a relatively long life expectancy are suitable. Select one species among these.

The specimens of test and control materials shall be implanted under the same conditions in the same species of the same age, sex and strain in corresponding anatomical sites. The number and size of implants inserted in an animal depends on the size of the species and the anatomical location.

### 3.3.2 Test periods

The local tissue response to implanted materials is assessed in short-term tests up to 12 weeks and in long-term tests exceeding 12 weeks.

Test periods are chosen to ascertain that a steady state has been reached with respect to biological response. The local biological response to implanted materials depends both on the properties of the materials and on the trauma of surgery. The tissue configuration found in the vicinity of an implant changes with the time elapsed after surgery. Usually, at one week observation periods, a high cell activity is found, followed by a transitional stage. In muscle and connective tissue, depending on the species, a steady state is seen in the cell population after 9 to 12 weeks. Implantation in bone tissues may need longer observation periods.

Test periods shall be selected from those specified in [table 1](#) for short-term implantation, or from [table 2](#) for long-term implantation.

<b>Table 1 — Selection of test periods for short-term implantation in subcutaneous tissue and muscle</b>					
Species	Implantation period				
	weeks				
	1	3	4	9	12
Mice	x	x		x	
Rats	x		x		x
Guinea-pigs	x		x		x
Rabbits	x		x		x

<b>Table 2—Selection of test periods for long-term implantation in subcutaneous tissue muscle and bone</b>					
Species	Implantation period				
	weeks				
	12	26	52	78	(104)
Rats	x	x	x		
Guinea-pigs	x	x	x		
Rabbits	x	x	x	x	
Dogs	x	x	x	x	x
Sheep	x	x	x	x	x
Goats	x	x	x	x	x
Pigs	x	x	x	x	x



Depending on the intended use of the test material, not all implantation periods may be necessary (see ISO 10993-1). An observation period of 104 weeks may be of interest in selected instances.

The number of implants per animal and the number of animals per observation period are described in clauses 4 to 6. A sufficient number of implants shall be inserted to ensure that the final number of specimens to be evaluated will give valid results.

### **3.3.3 Surgery**

Anesthetize the animals. Remove hair from the surgical area by clipping, shaving or other mechanical means. Wash the area with an antiseptic solution. Ensure that hair does not come in contact with the implants or the wound surfaces. The specific insertion or implantation procedures are described in clauses 4 to 6.

The surgical technique may profoundly influence the result of any implantation procedure. The surgery shall be carried out under aseptic conditions and in a manner that minimizes trauma at the implant site.

After surgery close the wound, using either wound clips or sutures, taking precautions to maintain aseptic conditions.

### **3.3.4 Post-operative assessment**

Observe each animal at appropriate intervals during the test period and record any abnormal findings, including local, systemic and behavioral abnormalities.

### **3.3.5 Euthanasia**

At the termination of the experimental period, euthanize the animals with an overdose of anesthetic or by some other acceptable humane method (see ISO 10993-2).

## **3.4 Evaluation of biological response**

Evaluate the biological response by grading and documenting the macroscopic and histopathological test responses as a function of time. Compare the responses to the test material and control material.

Carry out comparison of the control and the test implants at equivalent locations relative to each implant so that the effect of relative motion between the tissue and implant is at a minimum (see Note 2).

NOTE 2—For a cylindrical specimen the region is midway between its ends. With grooved cylindrical implants the center portions between the grooves as well as the flat top end surfaces of the implant are suitable for evaluation.

For a non-solid or particulate material incorporated into a tube, the area at the end of the tube is the only available area for evaluation.

### **3.4.1 Macroscopic assessment**

Examine each implant site with the aid of a low magnification lens. Record the nature and extent of any tissue reaction observed.

### **3.4.2 Preparation for histology—Implant retrieval and specimen preparation**

Excise the implant together with sufficient unaffected surrounding tissue to enable evaluation of the local biological response. Process the excised tissue blocks containing test or control implants for histopathological and other studies as appropriate.

When conventional techniques are used, the tissue envelope may be opened before or after exposure to a fixative and the condition of the implant surface and tissue bed shall be reported. However, with this technique the tissue layers closest to the implant are usually destroyed.

When the implant/tissue interface is to be studied, embedding of the intact tissue envelope with the implant *in situ* using hard plastics is preferred. Appropriate sectioning or grinding techniques are employed for the preparation of histological sections. It shall be demonstrated that the technique of embedding in plastics does not markedly alter the interface tissue.

### **3.4.3 Histological assessment**

The extent of response may be determined by measurement of the distance from the implant/tissue interface to unaffected areas with the characteristics of normal tissue and of normal vascularity. Record the section orientation in relation to the implant dimensions. Record the implant orientation, number of sections and cutting geometry.

The biological response parameters which shall be assessed and recorded include:

- a) extent of fibrosis/fibrous capsule and inflammation;
- b) degeneration as determined by changes in tissue morphology;
- c) number and distribution as a function of distance from the material/tissue interface of the inflammatory cell types, namely polymorphonuclear leucocytes, lymphocytes, plasma cells, eosinophils, macrophages and multinucleated cells;
- d) presence of necrosis as determined by nuclear debris and/or capillary wall breakdown;
- e) other parameters such as material debris, fatty infiltration, granuloma;
- f) for porous implant materials, the quality and quantity of tissue ingrowth.

In the case of bone, the interface between the tissue and the material is of special interest. Evaluate the area of bone contact and the amount of bone in the vicinity of the implant as well as the presence of intervening non-calcified tissues. Note the presence of bone resorption and bone formation.

## **3.5 Test report**

### **3.5.1 Content of test report**

The test report shall have sufficient detail to allow independent assessment of the results. The report shall include the items listed in [3.5.2](#) to [3.5.6](#).

### **3.5.2 Implant specimens**

Description of test and control materials, material condition, fabrication, surface condition, and the shape and size of implants.

Report the rationale for selection of control material(s).

The surface preparation of the specimens can affect the tissue reaction. Therefore, the preparation procedure should be noted in the report.

Report cleaning, handling and sterilization techniques employed. If not done in-house, this information should be supplied by the manufacturer before the investigation commences.

### **3.5.3 Animals and implantation**

Report origin, age, sex and strain of animals. Report housing conditions, diet and mass of animals during the study period. The health of the animals shall be evaluated during the study. All observations, including unexpected death, shall be reported.

Report insertion techniques. Report number of implants inserted per animal, per site and per observation period.

### **3.5.4 Retrieval and histological procedure**

The report shall include a description of the retrieval technique. The number of implants retrieved per animal and per observation period shall be recorded. All specimens shall be accounted for and considered as part of the test. The techniques employed for the fixation and preparation of the histological sections shall be described.

### **3.5.5 Evaluation**

Macroscopic observations shall include the observations made on each implant as well as the macroscopic appearance of the tissue surrounding the implant. The report shall include the results obtained from each histological examination.

### **3.5.6 Final evaluation**

The report shall include a comparative evaluation of the biological responses to test and control materials, as well as a descriptive narrative of the biological response.

## **4 Test method for implantation in subcutaneous tissue**

### **4.1 Field of application**

This test method is used for assessing the biological response of subcutaneous tissue to an implanted material.

The study may be used to compare the effect of different surface textures or conditions of the same material, or to assess the effect of various treatments or modifications of a material.

### **4.2 Principle**

Insertion of the implants in the subcutaneous tissue of test animals. The method compares the biological response to implants of test specimens with the biological response to implants of control specimens made of materials which are established in clinical use (see [3.2.3](#)).

### **4.3 Test specimens**

Common provisions for preparation of test and control specimens are described in [3.2](#). Implant sizes are based on the size of the test animal.

#### **4.3.1 Specimens made of sheet material shall be 10 mm to 12 mm in diameter and from 0.3 mm to 1 mm in thickness.**

NOTE 3—The subcutaneous site, deep to the panniculus carnosus muscle, is particularly suitable for the evaluation of polymeric sheet material. In an intramuscular site, sheet material may become folded, which makes it difficult to assess the effect of the material *per se*.

#### **4.3.2 Bulk materials shall be fabricated into specimens 1.5 mm in diameter and 5 mm in length, and have radiused ends.**

#### **4.3.3 Grooved specimens shall be 4 mm in diameter and 7 mm in length (see [annex B](#)).**

NOTE 4—Tissue ingrowth into the grooves minimizes tissue irritation caused by interface motion.

#### **4.3.4 Non-solid specimens (including powders) shall be prepared in tubes 1.5 mm in diameter and 5 mm in length (see [3.2.2](#)).**

### **4.4 Test animals and implant sites**

The implants shall be inserted in the dorsal subcutaneous tissue of adult mice, rats, guinea-pigs or rabbits.

Select one species among these.

Use at least three animals and sufficient sites to yield 10 specimens for each material and implantation period.

#### **4.5 Implantation procedure**

Select one of the procedures described in [4.5.1](#) and [4.5.2](#).

##### **4.5.1 Implantation along dorsal midline**

Make an incision of the skin and make one or more subcutaneous pockets by blunt dissection. The base of the pocket shall be more than 10 mm from the line of incision. Place one implant in each pocket. The implants shall not be able to touch one another.

NOTE 5—Alternatively, the implants may be delivered by a trocar to the desired site.

##### **4.5.2 Implantation in neck**

In mice, make a 10 mm long incision above the sacrum and prepare a subcutaneous tunnel by blunt dissection towards the neck. Push one implant (for design see annex B) through the tunnel to position it at the neck.

In rats, insert one implant of each of the control and candidate materials separately on each side of the neck. The implants shall not be able to touch one another.

At some distance from the implant, close the tunnel with stitches of appropriate suture material to prevent the implant from moving.

#### **4.6 Implantation period**

To ensure a steady state of biological tissue response the implantation period(s) shall be as specified in [3.3.2](#).

#### **4.7 Evaluation of biological response**

The evaluation shall take into account the items specified in [3.4](#).

#### **4.8 Format of test report**

The presentation of test results and final test report shall include the items specified in [3.5](#).

### **5 Test method for implantation in muscle**

#### **5.1 Field of application**

This test method is used for assessing the biological response of muscle tissue to an implanted material.

#### **5.2 Principle**

Insertion of the implant in the muscle of a test animal. The method compares the biological response to implants of test specimens with the biological response to implants of control specimens made of materials which are established in clinical use (see [3.2.3](#)).

#### **5.3 Test specimens**

Common provisions for preparation of test and control specimens are described in [3.2](#). Implant sizes are based on the size of the muscle group chosen.

For rabbit paravertebral muscles, implants of a width of 1 mm to 3 mm with a length of approximately 10 mm shall be used.

The specimens shall have rounded edges and the ends finished to a full radius.

#### **5.4 Test animals and implant sites**

Insert the implants in the muscle tissue of rabbits or other animals. Ensure that the muscles are of sufficient size to accommodate the implant specimens. Use only one species per test.

NOTE 6—The paravertebral muscles of rabbits are the preferred implant sites. Alternatively, the gluteal muscles of rats, or the thigh muscles of rabbits may be used.

Use at least three animals and sufficient implant sites to yield eight test specimens and eight control specimens for each implantation period.

In cases where the control material is expected to elicit more than a minimal response, use two specimens of this control. Implant two additional control specimens, composed of a material known to evoke a minimal tissue reaction, in a location opposite to the test materials.

#### **5.5 Implantation procedure**

Implantation shall be by hypodermic needle or trocar. For larger implants other appropriate surgical implantation techniques may be used.

Implant test specimens into the body of the muscle with the long axis parallel to the muscle fibers.

For rabbit paravertebral muscles, implant four specimens of the test materials along one side of the spine, 25 mm to 50 mm from the midline and parallel to the spinal column, and about 25 mm apart from each other. In similar fashion implant four specimens of the control material in the contralateral muscle of each animal.

#### **5.6 Implantation period**

To ensure a steady state of biological tissue response, the implantation period(s) shall be as specified in [3.3.2](#).

#### **5.7 Evaluation of biological response**

The evaluation shall take into account the items specified in [3.4](#).

#### **5.8 Format of test report**

The presentation of test results and final test report shall include the items specified in [3.5](#).

### **6 Test method for implantation in bone**

#### **6.1 Field of application**

This test method is used for assessing the biological response of bone tissue to an implanted material.

The study may be used to compare the effect of different surface textures or conditions of the same material, or to assess the effect of various treatments or modifications of a material.

#### **6.2 Principle**

Insertion of the implants into the bone tissue of test animals. The method compares the biological response to implants of test specimens with the biological response to implants of control specimens made of materials which are established in clinical use (see [3.2.3](#)).

#### **6.3 Test specimens**

Common provisions for preparation of test and control specimens are described in [3.2](#).

##### **6.3.1 Shape of implant specimens**

The specimens may be screw-shaped or threaded to provide initial stability of the implants in the bone. If preparation of a screw shape is impractical, a cylinder shape may be used.

### **6.3.2 Size of test specimens**

Implant sizes are based on the size of the test animal and bone chosen. The following dimensions shall be considered:

- a) rabbits: cylindrical implants 2 mm in diameter and 6 mm in length;
- b) dogs, sheep and goats: cylindrical implants 4 mm in diameter and 12 mm in length;
- c) rabbits, dogs, sheep, goats and pigs: 2 mm to 4.5 mm orthopaedic bone screw-type implants.

## **6.4 Test animals and implant sites**

### **6.4.1 Test animals**

The implants shall be inserted into the bone of dogs, sheep, goats, pigs or rabbits. Select one species among these. Species differences are important in bone physiology, and should be assessed before implantation procedures are initiated.

At least four rabbits, or at least two each of other animals, shall be used for each implantation period.

### **6.4.2 Implant sites**

Equivalent anatomical sites shall be used for test and control specimens. The test implants shall be contralateral to the control implants. Select the implant site to minimize the risk of mobility of the implant.

NOTE 7—The femur and tibia are suitable. Other sites may be considered.

The number of implant sites shall be as follows:

- a) in each rabbit there shall be a maximum of six implant sites: three for test specimens and three for control specimens;
- b) in each dog, sheep, goat or pig, there shall be a maximum of 12 implant sites; six for test specimens and six for control specimens. Do not insert more than 12 specimens in any one animal.

The size, mass and age of the animal and the implant site chosen should ensure that the implant placement does not cause significant risk of pathological fracture of the test site. In younger animals it is especially important to ensure that the implants avoid the epiphyseal area or other immature bone.

## **6.5 Implantation procedure**

Perform bone preparation using low drilling speed and intermittent drilling with profuse irrigation with physiological saline solution and suction, because overheating will result in local tissue necrosis.

It is important that the diameter of the implant and the implant bed in the bone match well enough to avoid ingrowth of fibrous tissue.

Expose the cortex of each femur or tibia and drill the appropriate number of holes to receive implants. For rabbits, prepare up to three holes; for larger animals prepare up to six holes. Ream to final diameter or tap screw thread before insertion. Insert cylinders by finger pressure to allow press fit. Tighten screw-shaped implants in place with an instrument capable of delivering a predetermined torque. Record the torque.

## **6.6 Implantation period**

To ensure a steady state of biological tissue response the implantation period(s) shall be as specified in [3.3.2](#).

## 6.7 Evaluation of biological response

The evaluation shall take into account the items specified in [3.4](#).

## 6.8 Format of test report

The presentation of test results and final test report shall include the items specified in [3.5](#).

# Annex A (informative)

## Control materials

### A.1 Response

The biological response to these materials is not defined as no response, but rather the response is used as a reference against which a reaction to another material is compared.

As a porous control material is not available at present, it is acceptable to use a dense control material for comparative purposes.

If the most appropriate control material is expected to elicit a tissue response greater than that normally observed with the control materials cited in this annex, samples of these latter materials may be implanted as controls to check the surgical technique.

### A.2 Metallic control materials

Stainless steel, cobalt-chromium, titanium and titanium alloys are used to fabricate control specimens. The biological response to these materials has been well characterized by their extensive use in research and clinical practice. See for further information ISO 5832, Parts 1 to 8, which are listed for convenience in [annex C](#) ([1] to [8]).

### A.3 Polymeric and ceramic control materials


Information on non-metallic control materials is to be found in [9], [10] and [11].

# Annex B (informative)

## Cylindrical specimen

An example of the shape and dimensions of a cylindrical specimen for implantation in mice is given in [figure B.1](#).

Dimensions in millimetres



**Figure B.-1 — Special cylinder with grooves**

## Annex C (informative)

### Bibliography

#### C.1 Control materials

- [1] ISO 5832-1:1987, *Implants for surgery — Metallic materials — Part 1: Wrought stainless steel.*
- [2] ISO 5832-2:1993, *Implants for surgery — Metallic materials — Part 2: Unalloyed titanium.*
- [3] ISO 5832-3:1990, *Implants for surgery — metallic materials — Part 3: Wrought titanium 6-aluminium 4-vanadium alloy.*
- [4] ISO 5832-4:1978, *Implants for surgery — Metallic materials — Part 4: Cobalt-chromium-molybdenum casting alloy.*
- [5] ISO 5832-5:1993, *Implants for surgery — Metallic materials — Part 5: Wrought cobalt-chromium-tungsten-nickel alloy.*
- [6] ISO 5832-6:1980, *Implants for surgery — Metallic materials — Part 6: Wrought cobalt-nickel-chromium-molybdenum alloy.*
- [7] ISO 5832-7:1994, *Implants for surgery — Metallic materials — Part 7: Forgeable and cold-formed cobalt-chromium-nickel-molybdenum-iron alloy.*
- [8] ISO 5832-8:1987, *Implants for surgery — Metallic materials — Part 8: Wrought cobalt-nickel-chromium-molybdenum-tungsten-iron alloy.*
- [9] ISO 5834-2:1985, *Implants for surgery — Ultra-high molecular weight polyethylene — Part 2: Molded forms.*
- [10] ISO 6474:1994, *Implants for surgery — Ceramic materials based on high purity alumina.*
- [11] BS 5736-2 PRS:1986, *Positive control plastic reference standard for implantation.*

#### C.2 National standards

- [12] ASTM F 748, *Practice for Selecting Generic Biological Test Methods for Materials and Devices.*
- [13] ASTM F 763, *Practice for Short-Term Screening of Implant Materials.*
- [14] ASTM F 981, *Practice for Assessment of Compatibility of Biomaterials for Surgical Implants with Respect to Effect of Materials on Muscle and Bone.*
- [15] NF S 90-703:1989, *Matériel médico-chirurgical — Implants chirurgicaux — Essais de tolérance d'un biomatériau destiné à entrer en contact avec les tissus musculaires et osseux: implantations à court terme et à long terme.*
- [16] UNI 9582-3:1990, *Biocompatibility of Medical Materials and Devices — Bone Implant Test.*
- [17] U.S. Pharmacopeia XXII:1990, *Biological reactivity tests, In-Vivo.*

#### C.3 Additional literature

- [18] COHEN, J. Assay of Foreign-Body Reaction, *Journal of Bone and Joint Surgery*, 41A, pp. 152-166 (1959).
- [19] FERGUSON, AB. Jr., LAING, PG. and HODGE, ES. The Ionization of Metal Implants in Living



Tissues, *Journal of Bone and Joint Surgery*, 42A, pp. 77-90, 1960.

- [20] GERET, V., RAHN, BA., MATHYS, R., STRAUMANN, F. and PERREN, SM. *In vivo* Testing of Tissue Tolerance of Implant Materials: Improved Quantitative Evaluation through Reduction of Relative Motion at the Implant Tissue Interface. From Current Concepts of Internal Fixation of Fracture. HK. Uhthoff (ed.). Springer Verlag, 1980.
- [21] GERET, V., RAHN, BA., MATHYS, R., STRAUMANN, F. and PERREN, SM. Chapter 35: A Method for Testing Tissue Tolerance for Improved Quantitative Evaluation Through Reduction of Relative Motion at the Implant-Tissue Interface. *Evaluation of Biomaterials*, GD. Winter, JL. Leray, K. de Groot (eds). John Wiley & Sons Ltd., 1980.
- [22] KAMINSKI, EJ., OGLESBY, RJ., WOOD, NK. and SANDRIK, J. The Behavior of Biological Materials at Different Sites of Implantation. *Journal of Biomedical Materials Research*, 2, pp. 81-88, 1968.
- [23] LAING, PG., FERGUSON, AB., Jr. and HODGE, ES. Tissue Reaction in Rabbit Muscle Exposed to Metallic Implants. *Journal of Biomedical Materials Research*, 1, pp. 135-149, 1967.
- [24] LANGE LAND, K., GUTTUSO, J., LANGE LAND, LL. and TOBON, G. Methods in the study of biological response to endodontic materials. Tissue response to N2 (root canal sealer). *Oral Surg*, 27, p. 522, 1969.
- [25] PIZZOFERRATO, S., SAVARINO, L., STEA, S. and TARABUSI, C. Result of Histological Grading on 100 cases of Hip Prosthesis Failure. *Biomaterials*, 9, pp. 314-318, 1988.
- [26] RAHN, BA., GERET, V., CAPAUL, C., LARDI, M. and SOLOTHURNMANN, B. Morphometric Evaluation of Tissue Reaction to Implants Using Low Cost Digitizing Techniques. *Clinical Applications of Biomaterials*, AJC. Lee, T. Albrektsson and P.-I. Branemark (eds). John Wiley & Sons Ltd., 1982.
- [27] TORNECK, CD. Reaction of Rat Connective Tissue to Polyethylene Tube Implants. *Oral Surg*, 21, p. 379, 1966.
- [28] TORNECK, CD. Reaction of Rat Connective Tissue to Polyethylene Implants, *Oral Surg*, 24, p. 674, 1967.
- [29] TURNER, E., LAWRENCE, WH. and AUTIAN, J. Subacute Toxicity Testing of Biomaterials Using Histological Evaluation of Rabbit Muscle Tissue. *Journal of Biomedical Materials Research*, 7, pp. 39-58, 1973.